Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

QuintilesIMS
Chubb
Moodys
Express Scripts
McKesson
Harvard Business School
Queensland Health
Chinese Patent Office
Cantor Fitzgerald

Generated: November 18, 2018

DrugPatentWatch Database Preview

Taro Pharm Company Profile

« Back to Dashboard

What is the competitive landscape for TARO PHARM, and when can generic versions of TARO PHARM drugs launch?

TARO PHARM has sixty-three approved drugs.

There are six US patents protecting TARO PHARM drugs. There are two tentative approvals on TARO PHARM drugs.

Summary for Taro Pharm
US Patents:6
Tradenames:49
Ingredients:45
NDAs:63
Patent Litigation for Taro Pharm: See patent lawsuits for Taro Pharm

Drugs and US Patents for Taro Pharm

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Taro Pharms North PSORCON diflorasone diacetate CREAM;TOPICAL 020205-001 Nov 20, 1992 DISCN Yes No ➤ Sign Up ➤ Sign Up
Taro Pharm NYSTATIN nystatin SUSPENSION;ORAL 062876-001 Feb 29, 1988 AA RX No No ➤ Sign Up ➤ Sign Up
Taro Pharm Inds Ltd TRIAMCINOLONE ACETONIDE triamcinolone acetonide CREAM;TOPICAL 040039-001 Nov 26, 1997 AT RX No No ➤ Sign Up ➤ Sign Up
Taro Pharm AMIODARONE HYDROCHLORIDE amiodarone hydrochloride TABLET;ORAL 075424-002 Dec 18, 2002 AB RX No No ➤ Sign Up ➤ Sign Up
Taro Pharm Inds Ltd DESLORATADINE desloratadine SOLUTION;ORAL 202592-001 Jun 30, 2015 AA RX No No ➤ Sign Up ➤ Sign Up
Taro Pharm FELBAMATE felbamate SUSPENSION;ORAL 206314-001 Jun 16, 2017 AB RX No No ➤ Sign Up ➤ Sign Up
Taro Pharm WARFARIN SODIUM warfarin sodium TABLET;ORAL 040301-007 Jul 15, 1999 AB RX No No ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for Taro Pharm

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Taro Pharms PLIAGLIS lidocaine; tetracaine CREAM;TOPICAL 021717-001 Jun 29, 2006 5,919,479 ➤ Sign Up
Taro Pharms TOPICORT desoximetasone SPRAY;TOPICAL 204141-001 Apr 11, 2013 5,990,100 ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for TARO PHARM drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Topical Spray 0.25% ➤ Subscribe 2013-12-18
➤ Subscribe Topical Lotion 0.5% ➤ Subscribe 2011-03-16

Supplementary Protection Certificates for Taro Pharm Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1458369/01 Switzerland ➤ Sign Up PRODUCT NAME: ADAPALENUM + BENZOYLIS PEROXIDUM; REGISTRATION NUMBER/DATE: SWISSMEDIC 58460 19.05.2009
2013025,C1304992 Lithuania ➤ Sign Up PRODUCT NAME: CLINDAMYCINUM + TRETINOINUM; REGISTRATION NO/DATE: LT/1/13/3279/001, 2013 04 26 LT/1/13/3279/002, 2013 04 26 PA1332/043/001 20130323
C/GB10/005 United Kingdom ➤ Sign Up PRODUCT NAME: ADAPALENE AND BENZOYL PEROXIDE; REGISTERED: DK 40440 20071218; UK PL10590/0057 20091111
C/GB05/030 United Kingdom ➤ Sign Up PRODUCT NAME: NITISINONE (2-(2-NITRO-4-TRIFLUOROMETHYLBENZOYL)-1,3-CYCLOHEXANEDIONE) OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: UK EU/1/04/303/001 20050221; UK EU/1/04/303/002 20050221; UK EU/1/04/303/003 20050221
C0042 Belgium ➤ Sign Up PRODUCT NAME: 2-(2-BENZOYL-SUBSTITUE)-1,3-CYCLOHEXANE-DIONES; REGISTRATION NO/DATE: 8452/B 19930121
C0008 Belgium ➤ Sign Up PRODUCT NAME: TAZAROTENE; NAT. REGISTRATION NO/DATE: NL22604 19970922; FIRST REGISTRATION: DE - 37393.00.00 19961203
C/GB08/005 United Kingdom ➤ Sign Up SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB08/005 GRANTED TO MERCK SHARP + DOHME CORP. IN RESPECT OF THE PRODUCT DESLORATADINE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN COMBINATION WITH PSEUDOEPHEDRINE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT OR ESTER, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6322 DATED 21 JULY 2010 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 31 JULY 2022.
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

QuintilesIMS
Argus Health
Farmers Insurance
AstraZeneca
Moodys
Queensland Health
Federal Trade Commission
McKinsey
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.